Considering these results, we further explored the outcome in terms of the PFS of group A and B based on the presence of at least two specific baseline characteristics considered as an indicator of more aggressive disease (bone marrow involvement, elevated LDH, elevated β2-microglobulin, extra-nodal disease, bulky disease, and the presence of B-symptoms). The gene discussed is HLA-G; the disease is glycogen storage disease VI.